Generic Name and Formulations:
Timolol (as maleate) 0.5%; oph soln; contains benzalkonium chloride.
Bausch & Lomb Inc.
Indications for ISTALOL:
Open-angle glaucoma. Ocular hypertension.
1 drop in affected eye(s) once daily in the AM.
Greater than 1st-degree AV block. Overt cardiac failure. Cardiogenic shock. Sinus bradycardia. Bronchial asthma. Severe COPD. History of bronchospasm. Not for use as a sole agent in angle-closure glaucoma.
History of cardiac failure. Discontinue at 1st sign of cardiac failure, and before surgery. Avoid abrupt cessation. Diabetes. May mask hypoglycemia, thyrotoxicosis. Myasthenia gravis. Cerebrovascular insufficiency. Contact lenses (remove; may reinsert 15 min after instillation). Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid other topical β-blockers. May potentiate systemic β-blockers, reserpine, hypoglycemics, and mydriatic effect of topical epinephrine. May be potentiated by quinidine. May cause conduction defects with digoxin, calcium channel blockers (avoid concomitant use in impaired cardiac function).
Local irritation (burning, stinging), blurred vision, cataract, conjunctival injection, infection, headache, hypertension, itching. Systemic β-blocker effects (eg, bronchospasm, bradycardia, cardiac failure, muscle weakness).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|